None listed
Conditions
Brief summary
This study will help us by comparing the efficacy of topical timolol with oral propranolol in treating the infantile hemangiomas, as oral propranolol has been used traditionally for its treatment but it has more side effects and requires monitoring for hypotension and hypoglycemia. topical timolol is established as a much safer alternative. So we want to find if it is also comparable with regarding to its efficacy and outcomes. This study will provide valuable insights for healthcare providers, policymakers, and families, ultimately contributing to the development of patient-centred care
Interventions
The pediatric population with simple superficial infantile hemangioma will be treated in two groups. One group will be treated with topical timolol applied thrice a day, Group A: Topical timolol (0.5% eye drops) 1 drop per cm2 applied topically 3 thrice a day to the hemangioma for 4 months. Monthly follow ups will be done for first 4 months to evaluate the response of the treatment in both groups.
Contact details of individuals will be obtained after consent for adherence to the follow ups.
Sponsors
King edward Medical University Lahore
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
1 Months to 12 Months
Healthy volunteers
No
Inclusion criteria
o Infants aged 1 to 12 months. o Diagnosed with superficial infantile hemangiomas with no complications requiring treatment. o Parental consent obtained
Exclusion criteria
o Infants with deep hemangiomas. o Infants with contraindications to beta-blockers (e.g., bradycardia, hypotension, asthma). o Infants with significant comorbidities that could affect the study outcomes
Outcome results
None listed